Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Hepatocellular 42Parkinson Disease 4, Autosomal Dominant Lewy Body 29Carcinoma, Renal Cell 26Endometrial Neoplasms 13Melanoma 10Neoplasms 8Uterine Cervical Neoplasms 7Cholangiocarcinoma 7Biliary Tract Neoplasms 7Liver Neoplasms 6Thyroid Neoplasms 5Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Neuroendocrine Tumors 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Neoplasm Metastasis 4Esophageal Squamous Cell Carcinoma 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Thyroid Carcinoma, Anaplastic 3Recurrence 3Kidney Neoplasms 3Esophageal Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Carcinoma, Adenoid Cystic 3Breast Neoplasms 3Brain Neoplasms 3Adenocarcinoma 3Vulvar Neoplasms 2

Interventions

tremelimumab 4Ipilimumab 4lenvatinib 3durvalumab 3Nivolumab 3pembrolizumab 2balstilimab 2Pemetrexed 2Carboplatin 2Bevacizumab 2spartalizumab 1relatlimab 1poly ICLC 1osimertinib 1cemiplimab 1Vemurafenib 1Vascular Endothelial Growth Factor A 1Standard of Care 1Platinum 1Peptides 1Paclitaxel 1Opdualag 1Docetaxel 1Capecitabine 1Blood Specimen Collection 1Axitinib 1Antibodies, Bispecific 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Diabetes Mellitus, Insulin-Dependent, 12 × lenvatinib × 1 year × Clear all
NCT04305054 2026-05-28

KEYMAKER-U02

Merck Sharp & Dohme LLC

Phase 1/2 Completed
335 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT07131501 2025-08-20

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
48 enrolled
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT04522323 2025-07-25

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

MedImmune LLC

Phase 1 Active not recruiting
67 enrolled
Genitourinary

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡